London, 11 January 2010 … BioCeramic Therapeutics Limited, an emerging leader in the field of novel biomaterials for healthcare, announced today the appointment of Ian Brown as CEO. This was part of a succession plan that was developed by the board of directors over the past six months for its chief executive officer position, which will see Daniel Green, BioCeramic Therapeutics outgoing founding CEO, remain as a Director on the Board of the company.
Prior to joining BioCeramic Therapeutics, Ian held senior executive positions with Chromogenix (previously Kabi Pharmacia) in Gothenburg Sweden, Instrumentation Laboratory in Milan Italy, Cordlife, SDP Technology and Avanti Capital. Ian has served as a non executive director on a number of boards and as Chair and deputy Chair. In addition to his significant international corporate and business experience, Ian has led teams in M&A transactions and post deal integration. His experience also covers start-ups, divestments and spin-outs, as well as private and public company capital raisings and IPO’s.
Ian is a member of the Course Advisory Committee for the Masters of Entrepreneurship and Innovation Degree at the Australian Graduate School of Entrepreneurship (AGSE). Ian has an MBA and is a Fellow of both the Australian Institute of Company Directors and Australian Institute of Management, and is an alumnus of both INSEAD in France and MBS in Australia. Additional information about Ian can be found at LinkedIn www.linkedin.com/in/ianbrown1.
“This is an incredibly exciting and dynamic time for BioCeramic Therapeutics,” said Brown. “I am honoured to have the opportunity to continue BioCeramic Therapeutics’ strong leadership and commitment to serving our shareholders and employees. BCT stood out from the crowd with its broad pipeline and nearness to the market with a range of development programmes including bioceramics for hard tissue treatment and flexible biomimetic scaffold for tissue engineering.”
Dr Stephan Rietiker, chairman of the board of directors, said: “We are excited to have Ian join BCT at this time. The company is in its strongest ever position and is now focused on commercial deals, licensing, marketing and product sales. We wish to thank Daniel Green for his dedication during the early years of the company’s development.”
Daniel Green said: “As companies grow and evolve, new people with the appropriate skills must take up the new challenges. I and my colleagues on the BCT Board of Directors have been fortunate in attracting an outstanding new chief executive, Ian Brown.”
Rietiker went on to say, “Ian’s background is in both large multinational and small to medium size companies in life sciences. He has worked in pharmaceuticals, devices and diagnostics internationally. He has the qualifications, experience and drive needed to deliver BCT’s shift to commercial deals, licensing, marketing and product sales.”
2009 saw a number of important developments for BioCeramic Therapeutics, as the company moves to become a commercial cash generating business. These include:
* appointment of a new chairman with tremendous international experience, Dr Steve Rietiker,
* closing a £1.2 million financing, bringing in a new investor, Longbow,
* securing two further Technology Strategy Board grants, and
* winning a prestigious ACES/Amgen International award for academic enterprise recognising achievements and potential.
About BioCeramic Therapeutics Limited
BioCeramic Therapeutics Limited is a pioneer in the exciting new field of regenerative medicine, bringing together some of the world’s best materials scientists, doctors, biologists and chemists in both private and public sectors. BCT is developing two families of implants designed to promote tissue regeneration. Initial applications are in orthopaedics and oral care, with plans to extend this to a wide range of other tissues important in human diseases. Please visit: www.bioceramictherapeutics.com.
